Please login to the form below

Not currently logged in
Email:
Password:

Amgen buys Irish Pfizer plant

Amgen is to purchase an Irish manufacturing facility from Pfizer, with the jobs of 280 workers set to be retained

California-based biotech Amgen is to purchase Pfizer's manufacturing facility in County Dublin, Ireland, taking over a workforce of 240 Pfizer employees, with 40 workers to remain employed by Pfizer.

Pfizer had previously announced the closure of the facility as part of plans to streamline the company following its £68bn acquisition of Wyeth.

Financial details of the deal remain undisclosed, with Amgen to manufacture Pfizer products at the facility for an interim period while Pfizer leases a portion of the facility from Amgen.

Following the interim period, Amgen said it intends to 'develop the capability to formulate and fill its biological products at the site,' which has freeze-dry product and liquid vial filling operations.

The company said it also intends to expand manufacturing capabilities at the plant in the future.

Madhu Balachandran, senior vice president, Amgen Manufacturing, spoke of the deal's potential for Amgen to grow on a global level: "As we expand internationally, the Dublin site will help us deliver a growing supply of Amgen medicines for patients worldwide."

Barry O'Leary, CEO of Industrial Development Authority (IDA) Ireland – the agency responsible for developing industry opportunities in the country – commented on the positive effect of the deal for Ireland.

"This investment by Amgen... gives a substantial boost to Ireland's life sciences sector," he said.

"The retention of the 240 jobs by Amgen and the 40 staff who will remain employed by Pfizer, in Dun Laoghaire, is also very welcome news for staff and management here."

14th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics